Core Insights - The company has revised its convertible bond issuance plan to focus on strategic transformation towards innovative drug development [1][2] - The previous acquisition project of Fangyuan Pharmaceutical has been removed due to high uncertainty related to its bankruptcy restructuring [1] - New projects have been added to enhance the focus on innovative drug research, including the III phase clinical study and registration of QHRD211 injection [1] Summary by Sections - **Convertible Bond Issuance Plan**: The company has systematically revised its plan for issuing convertible bonds, emphasizing a strategic shift towards innovative drug development [1][2] - **Project Adjustments**: The original project to acquire 100% of Fangyuan Pharmaceutical has been deleted from the funding plan, while new innovative drug research projects have been strengthened [1] - **Financial Data and Compliance**: The company updated its financial data and disclosure periods to ensure timely and compliant information disclosure, with all related documents revised accordingly [2] - **Management Decision**: The revision of the convertible bond plan reflects a cautious decision by the management to eliminate high-uncertainty projects and concentrate resources on innovative drug development [2]